Related Experiment Video
Updated: Jan 28, 2026

Employing Aeroponic Systems for the Clonal Propagation of Cannabis
Published on: December 1, 2021
Promoting cannabis products to pharmaceutical drugs
Hinanit Koltai1, Patrick Poulin2, Dvory Namdar1
1Institute of Plant Science, Agriculture Research Organization, Volcani Center, Rishon LeZion 7528809, Israel.
Abstract:
Cannabis sativa is widely used for medical purposes. However, to date, aroma, popular strain name or the content of two phytocannabinoids-Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are mostly considered for therapeutic activity. This is despite the hundreds of compounds in this plant and their potential synergistic interactions in mixtures. New, specific and effective cannabis-based drugs must be developed to achieve adequate medical standards for the use of cannabis. To do this, the comprehensive molecular profile of cannabis-based drugs must be defined, and mixtures of compounds should be tested for superior therapeutic activity due to synergistic effects compared to individually isolated cannabis compounds. The biological pathways targeted by these new drugs should also be characterized more accurately. For drug development and design, absorption, distribution, metabolism and elimination versus toxicity (ADME/Tox) must be characterized, and therapeutic doses identified. Promoting the quality and therapeutic activity of herbal or synthetic cannabis products to pharma grade is a pressing need worldwide.
Related Concept Videos
Factors Influencing Drug Absorption: Pharmaceutical Parameters
Drug Product Stability
Pharmaceutical Equivalents
The Eukaryotic Promoter Region
Drug Products: Biologics, Biosimilars and Interchangeables
Drug Product Performance: In Vitro–In Vivo Correlation

